The stock's rise snapped a three-day losing streak.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Regeneron stock just slipped on a banana peel, hitting a 52-week low at $493.15 before closing at $496.06. Despite this dip, ...

He spotted the opportunity to invest in weight-loss drugs in 2023 before they exploded in 2024, and was an early AI mover, which he spied as a game changer in late 2022, early 2023. It's all about ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Decades ago, research conducted by Nobel laureates Eugene Fama and Kenneth French posited that small-cap stocks should deliver a premium for investors over the long term, due to the higher risk of ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) announced favorable Phase 3 trial results for itepekimab and entered a significant licensing agreement with Telesis Bio, enhancing its R&D capabilities.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Real-time index price for Nasdaq Dividend Achievers (DIVQ), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently entered a licensing agreement with Telesis Bio Inc. to implement the Gibson SOLA™ platform, aiming to boost the company’s efficiency in the biotech ...